Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed
expectations, driving an ever-expanding number of clinical trials and the first US Food and …

Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …

Cellular senescence is characterized by stable cell-cycle arrest and a secretory program that
modulates the tissue microenvironment,. Physiologically, senescence serves as a tumour …

The immunosuppressive microenvironment of solid tumours reduces the antitumour activity
of chimeric antigen receptor T cells (CAR-T cells). Here, we show that the release—through …

Malignant brain tumours are complex ecosystems containing neoplastic and stromal
components that generate adaptive and evolutionarily driven aberrant tissues in the central …

Chimeric antigen receptor (CAR)-T cells showed great activity in hematologic malignancies.
However, heterogeneous antigen expression in tumor cells and suboptimal CAR-T-cell …

Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a
result of tumor heterogeneity, immunosuppressive microenvironments, and inadequate …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumor in adults. Current treatment options typically consist of surgery followed by …

Malignant brain tumors, including glioblastoma, represent some of the most difficult to treat
of solid tumors. Nevertheless, recent progress in immunotherapy, across a broad range of …

Glioblastoma (GB) is the most common and aggressive primary brain tumor in adults and
currently incurable. Despite multimodal treatment regimens, median survival in unselected …